title: Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.
abstract: OBJECTIVE
  The aim was to develop clinical practice guidelines on hypertriglyceridemia.
  
  
  METHODS
  The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration.
  
  
  METHODS
  Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments.
  
  
  CONCLUSIONS
  The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein cholesterol level in agreement with National Cholesterol Education Program Adult Treatment Panel guidelines. The initial treatment should be lifestyle therapy; a combination of diet modification and drug therapy may also be considered. In patients with severe or very severe hypertriglyceridemia, a fibrate should be used as a first-line agent.
authors.affiliation: University of California, Davis, Sacramento, California 95817, USA.
authors.forename: Lars
authors.initials: L
authors.lastname: Berglund
authors.forename: John D
authors.initials: JD
authors.lastname: Brunzell
authors.forename: Anne C
authors.initials: AC
authors.lastname: Goldberg
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Goldberg
authors.forename: Frank
authors.initials: F
authors.lastname: Sacks
authors.forename: Mohammad Hassan
authors.initials: MH
authors.lastname: Murad
authors.forename: Anton F H
authors.initials: AF
authors.lastname: Stalenhoef
mesh_terms: D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D006801:Humans; D015228:Hypertriglyceridemia / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D009626:Terminology as Topic; D014280:Triglycerides / Q000097:blood
chemical_list: D014280:Triglycerides